Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$83,615.00-3.10%ETH$2,576.40-5.09%GOLD$4,147.20-0.95%OIL$89.85+0.46%
Smart Investors Daily
SID Premium
RA

NASDAQ · RANI

Rani Therapeutics Holdings, Inc.

Healthcare · Biotechnology

$0.83

Up+$0.05 (+6.96%)

Updated Oct 7, 2026, 12:11 PM

SID Score

3.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
107.3M
P/E ratio
-1.81
Dividend yield
0.00%
52-week range
$0.61 – $1.41
Volume
961.67K
Avg. volume
18.16M

Price performance · RANI

RANI price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

RANI closed at $0.83 after 21 trading sessions, down 5.01% for the selected period.

Last close
$0.83
Period change
-5.01%
Period low
$0.75
Period high
$0.87
Daily close
View OHLC price history
RANI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$0.7969$0.8304$0.7804$0.8288961.67K
Oct 5, 2026$0.84$0.8402$0.7701$0.7749582.53K
Oct 2, 2026$0.8077$0.8297$0.7982$0.8108418.52K
Oct 1, 2026$0.819$0.8517$0.7911$0.7955484.9K
Sep 30, 2026$0.81$0.8211$0.78$0.791468.36K
Sep 29, 2026$0.80$0.8225$0.778$0.8003405.62K
Sep 28, 2026$0.7595$0.7998$0.74$0.776624.8K
Sep 25, 2026$0.755$0.775$0.7306$0.7592382.62K
Sep 24, 2026$0.7773$0.7856$0.749$0.749607.39K
Sep 23, 2026$0.81$0.81$0.767$0.767648.58K
Sep 22, 2026$0.80$0.8298$0.7753$0.7779652.03K
Sep 21, 2026$0.8644$0.8698$0.7894$0.7894681.3K
Sep 18, 2026$0.85$0.862$0.8202$0.862386.98K
Sep 17, 2026$0.759$0.862$0.759$0.8516665.04K
Sep 16, 2026$0.8101$0.84$0.755$0.7561.44M
Sep 15, 2026$0.8343$0.849$0.7938$0.8215733.97K
Sep 14, 2026$0.85$0.8592$0.8311$0.8358372.88K
Sep 11, 2026$0.85$0.8539$0.8302$0.8426312.33K
Sep 10, 2026$0.85$0.85$0.822$0.822190.02K
Sep 9, 2026$0.878$0.8786$0.8392$0.84317.78K
Sep 8, 2026$0.873$0.8972$0.86$0.8725531.88K

Latest RANI news

The latest Smart Investors Daily articles mentioning RANI.

Stock researchCompany · Overview

RANI research

Overview

Company profile and research snapshot.

Company profile

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$15.67
Implied upside
—
Analysts
—
RANI recent ratings
DateFirmRatingTarget
Aug 21, 2026HC Wainwright & Co.Buy—
Aug 18, 2026Chardan CapitalBuy—
May 20, 2026Canaccord GenuityBuy—
Apr 1, 2026Canaccord GenuityBuy—
Mar 27, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 24, 2025

Rani Therapeutics to Participate in the Evercore Healthcare Conference

SAN JOSE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company’s management team will participate in the upcoming Evercore Healthcare Conference. Details below: 8th Annual Evercore Healthcare ConferenceDate: Wednesday, December 3, 2025 at 8:45 am E.T.Location: Coral Gables, FLPresenter: Chief Executive

globenewswire.com · Nov 24, 2025

Rani Therapeutics to Participate in the Evercore Healthcare Conference

SAN JOSE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company's management team will participate in the upcoming Evercore Healthcare Conference. Details below:

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By